Effect of Oral Isosorbide Mononitrate Plus Amlodipine Antispasm Therapy on Outcomes of Radial Artery Grafts After CABG
Launched by RUIJIN HOSPITAL · Dec 8, 2024
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a combination of two medications, oral isosorbide mononitrate and amlodipine, can help improve the success of radial artery grafts in patients who have undergone coronary artery bypass graft surgery (CABG). The main goal is to find out if this treatment can reduce the chances of these grafts failing after the surgery.
To participate in the trial, you need to be at least 18 years old and have had CABG surgery using a radial artery graft within the last three days. If you join, you will take the medications daily for 24 weeks and have follow-up visits at 1, 4, 12, and 24 weeks after your surgery to monitor your health. Researchers will also perform a special imaging test at the end of the 24 weeks to check the condition of the grafts. This trial is not yet recruiting participants, but it aims to help improve outcomes for patients like you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age≥18 years old，
- • Any sex，
- • Signed informed consent，
- • Within 3 days after primary isolated CABG using RA graft
- Exclusion Criteria:
- • 1. Allergy to isosorbide mononitrate or amlodipine.
- • 2. Hypotension (systolic BP \<90 mmHg or diastolic BP \<60 mmHg)
- • 3. Acute myocardial infarction or cardiogenic shock
- • 4. Contraindications for CCTA examination (eg., iodine allergy)
About Ruijin Hospital
Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, is a leading medical institution in China recognized for its commitment to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care, Ruijin Hospital integrates cutting-edge medical practices with rigorous scientific investigation. The hospital's multidisciplinary teams are dedicated to developing new therapeutic approaches, improving patient outcomes, and contributing to global medical knowledge. As a sponsor of clinical trials, Ruijin Hospital ensures adherence to the highest ethical standards and regulatory compliance, fostering an environment of collaboration and excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Patients applied
Trial Officials
Qiang Zhao, MD
Principal Investigator
Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China
Mario FL Gaudino, MD
Principal Investigator
Weill Cornell Medicine NewYork Presbyterian Hospital, NY, US
Yunpeng Zhu, MD
Study Director
Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported